
Modeling and docking analysis of GPR87 with anti-cancer drugs
Abstract
Keywords
References
Hans BO, Petrine W, Anders AJ: Structure, Pharmacology and Therapeutic Prospects of Family C G-Protein Coupled Receptors. Current Drug Targets 2007, 8: 169-184.
http://dx.doi.org/10.2174/138945007779315614
Shore DM, Reggio PH: The therapeutic potential of orphan GPCRs, GPR35 and GPR55. Front Pharmacol. 2015, 15: 6-69.
http://dx.doi.org/10.3389/fphar.2015.00069
Tabata K, Baba K, Shiraishi A, Ito M, Fujita N: The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem.Biophys. Res. Commun 2007, 363: 861-866.
http://dx.doi.org/10.1016/j.bbrc.2007.09.063
Gugger M, White R, Song S: GPR87 is an over expressed G-protein coupled receptor in squamous cell carcinoma of the lung. Dis Markers 2008, 24: 41–50.
http://dx.doi.org/10.1155/2008/857474
Pierce KL, Premont RT, Lefkowitz RJ: Seven-transmembrane receptors. Nat Rev Mol Cell Biol 2002, 3: 639-650.
http://dx.doi.org/10.1038/nrm908
Nonaka Y, Hiramoto H, Fujita N: Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods. Biochem. Biophys. Res. Commun 2005, 337: 281-288.
http://dx.doi.org/10.1016/j.bbrc.2005.09.052
Wittenberger T, Schaller HC, Hellebrand S: An expressed sequence tag (EST) data mining strategy succeeding in the discovery of new Gprotein coupled receptors. J Mol Biol 2001, 307: 799-813.
http://dx.doi.org/10.1006/jmbi.2001.4520
Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ: Basic local alignment search tool. J Mol. Biol 1990, 215(3): 403–410.
http://dx.doi.org/10.1016/S0022-2836(05)80360-2
Arnold K, Bordoli L, Kopp J, Schwede T: The SWISS-MODEL workspace: a web-based environment for protein structure homology modeling. Bioinformatics 2006, 22: 195-201.
http://dx.doi.org/10.1093/bioinformatics/bti770
Wu B, Chien EY, Mol CD, et al.: Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists. Science 2010, 330(6007): 1066-1071.
http://dx.doi.org/10.1126/science.1194396
Laskowski RA, MacArthur MW, Moss DS, Thornton JM: PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Cryst 1993, 26: 283-291.
http://dx.doi.org/10.1107/S0021889892009944
Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M: CHARMM: a program for macromolecular energy minimization and dynamics calculations. J Comput Chem 1993, 4: 187–217.
http://dx.doi.org/10.1002/jcc.540040211
Accelrys Software Inc., Cerius2 Modeling Environment, Release 4.7, Accelrys Software Inc., San Diego, 2003.
Rani M, Nischal A, Sahoo, GC, Khattri, S: Computational Analysis of the 3-D structure of Human GPR87 Protein: Implications for Structure-Based Drug Design. Asian Pac J Cancer Prev 2013, 14 (12): 7473-7482.
http://dx.doi.org/10.7314/APJCP.2013.14.12.7473
Zhang Z, Li Y, Lin B, Schroeder M, Huang B: Identification of cavities on protein surface using multiple computational approaches for drug binding site prediction. Bioinformatics 2011, 27(15): 2083-2088.
http://dx.doi.org/10.1093/bioinformatics/btr331
Dundas J, Ouyang Z, Tseng J, Binkowski A, Turpaz Y, Liang J: CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acid Research 2006, 34: 116-118.
http://dx.doi.org/10.1093/nar/gkl282
Venkatachalam CM, Jiang X, Oldfield T, Waldman M: LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graphics Modelling 2003, 21: 289–307.
http://dx.doi.org/10.1016/S1093-3263(02)00164-X
Mayo SL, Olafson BD, Goddard WA III: Dreiding: ageneric force forcefield for molecular simulation. J Phys Chem 1990, 94: 8897–8909.
http://dx.doi.org/10.1021/j100389a010
Lipinski CA: Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2001, 44: 235–249.
http://dx.doi.org/10.1016/S1056-8719(00)00107-6
Lipinski CA, Lombardo F, Dominy BW, Feeney JP: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development setting. Adv Drug Deliv Rev 2001, 46: 3–26.
http://dx.doi.org/10.1016/S0169-409X(00)00129-0
DOI: http://dx.doi.org/10.14259%2Fbp.v3i1.173
Refbacks
- There are currently no refbacks.